Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(32 sites)
United States
City of Hope, Duarte, California Colorado Blood Cancer Institute, Denver, Colorado University of Iowa Hospital and Clinics, Iowa City, Iowa University of Kentucky Medical Center, Lexington, Kentucky Rutgers Cancer Institute of New Jersey, Piscataway, New Jersey Levine Cancer Institute, Charlotte, North Carolina University Hospitals Cleveland Medical Center, Cleveland, Ohio University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania Greco Hainesworth Tennessee Oncology Centers for Research, Nashville, Tennessee Sarah Cannon Research Institute, Nashville, Tennessee St. David's South Austin Medical Center, Austin, Texas MD Anderson Cancer Center, Houston, Texas Texas Transplant Institute, San Antonio, Texas Swedish Cancer Institute, Seattle, Washington Australia
St Vincents Hospital Melbourne, Fitzroy The Alfred Hospital, Melbourne Fiona Stanley Hospital, Murdoch Calvary Mater Newcastle Hospital, Waratah Canada
Princess Margaret Cancer Centre University Health Network, Toronto, Ontario Denmark
Rigshospitalet, Copenhagen Odense University Hospital, Odense South Korea
Seoul National University Hospital, Seoul Asan Medical Center, Seoul Samsung Medical Center, Seoul Spain
Hosp Univ Vall D Hebron, Barcelona Hosp Clinic de Barcelona, Barcelona ICO L'Hospitalet - Hospital Duran i Reynals, Barcelona Hosp Univ Fund Jimenez Diaz, Madrid United Kingdom
University College London Hospitals, London The Christie NHS Foundation Trust Christie Hospital, Manchester